Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2026-03-27 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药关于续聘审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the company's decision to continue appointing an audit firm (Lixin Certified Public Accountants) for the 2026 fiscal year. It details the audit firm's background, independence, audit fees, and the board's approval of the reappointment. The document does not contain any actual financial statements or audit reports but is a formal notice about the appointment of the audit institution. The document length is 4128 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates specifically to audit matters and the appointment of the audit firm, but it is not the audit report itself. However, given the document is primarily an announcement of the audit firm appointment and related information, it fits the Audit Report / Information (AR) category rather than a full Annual Report or Interim Report.
2026-03-27 Chinese
国邦医药董事会关于独立董事独立性情况的专项报告
Governance Information Classification · 95% confidence The document is a special report on the independence of the company's independent directors, referencing regulatory guidelines such as the 'Measures for the Administration of Independent Directors of Listed Companies' and the 'Shanghai Stock Exchange Listing Rules'. It evaluates the independence of specific directors and confirms compliance with relevant independence requirements. The document is short (431 characters) and focuses on governance and compliance related to board members' independence, not financial data or audit results. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2026-03-27 Chinese
国邦医药2025年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2025年度董事会审计委员会履职情况报告" which translates to the "2025 Annual Board Audit Committee Performance Report." It details the activities, meetings, and evaluations conducted by the audit committee during the year 2025, including oversight of external auditors, internal audit guidance, internal control assessments, and related governance matters. The content focuses on the audit committee's work and its evaluation of the external audit firm and internal controls, rather than presenting the full annual financial statements or the entire annual report. This type of document is a standalone audit-related report describing audit committee activities and audit results, which fits the category of an Audit Report / Information (AR). The document length is 3162 characters, which is relatively short but contains substantive audit committee content rather than just an announcement or certification. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Hence, the best classification is AR with high confidence.
2026-03-27 Chinese
国邦医药2025年度环境、社会与公司治理（ESG）报告
Environmental & Social Information Classification · 95% confidence The document is titled as the "2025年度环境、社会与公司治理（ESG）报告" which translates to the "2025 Environmental, Social and Governance (ESG) Report". It covers detailed ESG performance, governance structure, social responsibility, environmental protection, and company management practices for the full fiscal year 2025. The report includes comprehensive sections on ESG strategy, governance, social responsibility, environmental protection, and investor relations, with data and analysis consistent with an ESG report. It is a full report, not a brief announcement or a certification. The document length is substantial (15,000 characters), indicating it is the full report itself. This matches the definition of Environmental & Social Information (Code: SR), which covers detailed ESG performance reports. Therefore, the correct classification is SR with high confidence.
2026-03-27 Chinese
国邦医药关于公司及子公司开展外汇套期保值业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Guobang Pharmaceutical Group Co., Ltd. regarding the company's and its subsidiaries' engagement in foreign exchange hedging business. It details the transaction purpose, amount, funding source, transaction method, term, approval procedures, risk analysis, risk control measures, and accounting treatment. The document is relatively short (2858 characters) and structured as a formal announcement with no financial statements or detailed financial data. It does not present a full financial report or interim report but rather informs about a specific capital/financing activity related to foreign exchange hedging. This fits the definition of a Capital/Financing Update (CAP) as it updates on company financing activities and risk management related to capital use. It is not a report publication announcement or regulatory filing since it contains substantive information about the transaction itself, not just a notice of report availability or certification.
2026-03-27 Chinese
国邦医药关于召开2025年年度股东会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2025 Annual General Meeting (AGM) of Guobang Pharmaceutical Group Co., Ltd., including details such as meeting date, voting methods, agenda items, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather the announcement and procedural information for the AGM. The document length is 3196 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2026-03-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.